COVID-19 Drug Development.
J Microbiol Biotechnol
; 32(1): 1-5, 2022 Jan 28.
Article
in English
| MEDLINE | ID: covidwho-1555623
ABSTRACT
Diagnostics, vaccines, and drugs are indispensable tools and control measures employed to overcome infectious diseases such as coronavirus disease 2019 (COVID-19). Diagnostic tools based on RT-PCR were developed early in the COVID-19 pandemic and were urgently required for quarantine (testing, tracing and isolation). Vaccines such as mRNA vaccines and virus-vectored vaccines were also successfully developed using new platform technologies within one year after identifying severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as the causative agent of COVID-19. Drug development has been conducted in various ways including drug repurposing, convalescent plasma therapy, and monoclonal antibody development. Among the above efforts, this review examines COVID-19 drug development along with the related and upcoming challenges.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Drug Repositioning
/
Drug Development
/
SARS-CoV-2
/
COVID-19
/
COVID-19 Drug Treatment
Type of study:
Diagnostic study
/
Prognostic study
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
J Microbiol Biotechnol
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS